NCT00443391View on ClinicalTrials.gov

A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)

PHASE2CompletedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
DRUG

ABT-089

Open label study, subjects will take up to 80mg daily for 24 months.

Trial Locations (21)

10010

Site Reference ID/Investigator# 6099, New York

20170

Site Reference ID/Investigator# 6095, Herndon

27514

Site Reference ID/Investigator# 6106, Chapel Hill

29405

Site Reference ID/Investigator# 6097, Charleston

30080

Site Reference ID/Investigator# 6094, Smyrna

32216

Site Reference ID/Investigator# 6112, Jacksonville

32751

Site Reference ID/Investigator# 6096, Maitland

33606

Site Reference ID/Investigator# 6105, Tampa

38119

Site Reference ID/Investigator# 6098, Memphis

48336

Site Reference ID/Investigator# 6113, Farmington Hills

53562

Site Reference ID/Investigator# 6101, Middleton

67114

Site Reference ID/Investigator# 6111, Newton

68198

Site Reference ID/Investigator# 6110, Omaha

77566

Site Reference ID/Investigator# 6104, Lake Jackson

78704

Site Reference ID/Investigator# 6103, Austin

85210

Site Reference ID/Investigator# 6109, Mesa

Site Reference ID/Investigator# 6765, Mesa

94549

Site Reference ID/Investigator# 6100, Lafayette

97210

Site Reference ID/Investigator# 6102, Portland

98104

Site Reference ID/Investigator# 6092, Seattle

92103-8620

Site Reference ID/Investigator# 6107, San Diego

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT00443391 - A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD) | Biotech Hunter | Biotech Hunter